Gene therapy: No improvement in outcomes with gene therapy for heart failure

@article{FernandezRuiz2016GeneTN,
  title={Gene therapy: No improvement in outcomes with gene therapy for heart failure},
  author={I. Fernández-Ruíz},
  journal={Nature Reviews Cardiology},
  year={2016},
  volume={13},
  pages={122-123}
}
2 Citations

Topics from this paper

New insights into SERCA2a gene therapy in heart failure: pay attention to the negative effects of B-type natriuretic peptides
TLDR
The current knowledge of SERCA2a gene therapy for heart failure is summarised, potential interaction between BNP levels and therapeutic effects ofSERCA 2a gene transfer is analysed and directions for future research to solve the identified problems are provided. Expand
RNA Sequencing Reveals Novel Transcripts from Sympathetic Stellate Ganglia During Cardiac Sympathetic Hyperactivity
TLDR
Key changes in the transcriptome in normotensive and spontaneously hypertensive rats are identified, suggesting that key genes coupled to neurotransmission are conserved and may provide novel targets for future interventions aimed at treating sympathetic hyperactivity associated with cardiovascular disease and other dysautonomias. Expand

References

Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
TLDR
Although the authors did not find evidence of improved outcomes at the dose of AAV1/SERCA2a studied, the findings should stimulate further research into the use of gene therapy to treat patients with heart failure and help inform the design of future gene therapy trials. Expand